Adrianne2018 - Modelling combined virotherapy and immunotherapy: strengthening the antitumour immune response mediated by IL-12 and GM-CSF expression Lab

{
  "io": {
    "inputs": [
      {
        "name": "initial_unresolved_tumor_observable_1",
        "label": "Initial Unresolved Tumor Observable 1",
        "units": "native source value",
        "default": 85,
        "maps_to": "immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model.initial_unresolved_tumor_observable_1",
        "description": "Initial Unresolved Tumor Observable 1. Sets the initial value of bundled SBML species `U`."
      },
      {
        "name": "initial_unresolved_tumor_observable_2",
        "label": "Initial Unresolved Tumor Observable 2",
        "units": "native source value",
        "default": 0,
        "maps_to": "immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model.initial_unresolved_tumor_observable_2",
        "description": "Initial Unresolved Tumor Observable 2. Sets the initial value of bundled SBML species `I`."
      },
      {
        "name": "initial_unresolved_tumor_observable_3",
        "label": "Initial Unresolved Tumor Observable 3",
        "units": "native source value",
        "default": 0,
        "maps_to": "immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model.initial_unresolved_tumor_observable_3",
        "description": "Initial Unresolved Tumor Observable 3. Sets the initial value of bundled SBML species `V`."
      },
      {
        "name": "initial_unresolved_tumor_observable_4",
        "label": "Initial Unresolved Tumor Observable 4",
        "units": "native source value",
        "default": 0,
        "maps_to": "immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model.initial_unresolved_tumor_observable_4",
        "description": "Initial Unresolved Tumor Observable 4. Sets the initial value of bundled SBML species `A`."
      },
      {
        "name": "initial_unresolved_tumor_observable_5",
        "label": "Initial Unresolved Tumor Observable 5",
        "units": "native source value",
        "default": 0,
        "maps_to": "immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model.initial_unresolved_tumor_observable_5",
        "description": "Initial Unresolved Tumor Observable 5. Sets the initial value of bundled SBML species `H`."
      }
    ],
    "outputs": [
      {
        "name": "unresolved_tumor_observable_1",
        "maps_to": "immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model.unresolved_tumor_observable_1"
      },
      {
        "name": "unresolved_tumor_observable_2",
        "maps_to": "immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model.unresolved_tumor_observable_2"
      },
      {
        "name": "unresolved_tumor_observable_3",
        "maps_to": "immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model.unresolved_tumor_observable_3"
      },
      {
        "name": "unresolved_tumor_observable_4",
        "maps_to": "immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model.unresolved_tumor_observable_4"
      },
      {
        "name": "unresolved_tumor_observable_5",
        "maps_to": "immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model.unresolved_tumor_observable_5"
      },
      {
        "name": "state",
        "maps_to": "immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model.state"
      },
      {
        "name": "summary",
        "maps_to": "immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model.summary"
      },
      {
        "name": "species_labels",
        "maps_to": "immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model.species_labels"
      }
    ]
  },
  "title": "Adrianne2018 - Modelling combined virotherapy and immunotherapy: strengthening the antitumour immune response mediated by IL-12 and GM-CSF expression Lab",
  "models": [
    {
      "path": "models/core",
      "alias": "immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model"
    },
    {
      "path": "models/visualisation",
      "alias": "visualisation"
    }
  ],
  "wiring": [
    {
      "to": [
        "visualisation.immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model_state"
      ],
      "from": "immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model.state"
    },
    {
      "to": [
        "visualisation.immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model_summary"
      ],
      "from": "immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model.summary"
    },
    {
      "to": [
        "visualisation.immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model_species_labels"
      ],
      "from": "immunology_sbml_adrianne2018_modelling_combined_virotherapy_and_model1912120003_model.species_labels"
    }
  ],
  "package": "adrianne2018-modelling-combined-virotherapy-and-immunot-890d964c",
  "runtime": {
    "duration": 10,
    "initial_inputs": {},
    "communication_step": 1
  },
  "version": "1.0.1",
  "description": "Modelling combined virotherapy and immunotherapy:strengthening the antitumour immune response mediated byIL-12 and GM-CSF expressionAdrianne L. It can be used to explore immune response dynamics and compare pathway-level behavior across conditions.",
  "schema_version": "2.0"
}